top of page

英語論文 2014-2024

9P6A9055.JPG
9P6A9083.JPG

【2024】(IF = 21.9)

  1. Kunimune Y, Suehiro Y, Saeki I, Yamauchi Y, Tanabe N, Matsumoto T, Higaki S, Fujii I, Suzuki C, Okayama N, Nishioka M, Ichihara K, Nagano H, Sakaida I, Takami T, Yamasak T. Combination Assay of Methylated HOXA1 with Tumor Markers Shows High Sensitivity for Detection of Early-Stage Hepatocellular Carcinoma. Liver Cancer. On line first. https://doi.org/10.1159/000536211 (IF = 13.8)

  2. Yamauchi Y, Saeki I, Fujisawa K, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Sasaki R, Nishimura T, Tanabe N, Hisanaga T, Matsumoto T, Ishikawa T, Yamasaki T, Takami T. Varying Impact of Lenvatinib or Sorafenib Therapy on Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma. Oncology. 2024 Jan 29;1-6. (IF = 3.5)

  3. Wasai Y, Yamada N, Ariyoshi N, Haraguchi A, Funatsu M, Mikuni M, Nakamura R, Sakuma A, Higashijima F, Iwamoto N, Teranishi S, Nishioka M, Yamasaki T, Kimura K. SARS-CoV-2 infection status in corneal preservation solution and COVID-19 prevalence after corneal transplantation. Scientific Reports. 2024 Feb 14; 14:3766(2024). (IF = 4.6)

​

【2023】(IF = 39.1)​

  1. Ozaki M, Kobayashi T, Fujinaga A, Nishioka M, Shikichi K, Okano S, Sakai Y, Fujii S, Matsui N, Takasago M, Okada N, Yamasaki T, Kitahara T. Influence of filtering on the effective concentration and sterility of a 2% cyclosporine ophthalmic solution: a quality improvement perspective. J Pharm Health Care Sci. 2023 Dec 27;9(1):50. (IF = 1.0/2022)

  2. Fujisawa K, Matsumoto T, Yamamoto N, Yamasaki T, Takami T. Metabolic Analysis of DFO-Resistant Huh7 Cells and Identification of Targets for Combination Therapy. Metabolites. 2023 Oct 12;13(10):1073. (IF = 4.1)

  3. Fukano R, Iijima-Yamashita Y, Iwafuchi H, Nakazawa A, Saito AM, Takimoto T, Sekimizu M, Suehiro Y, Yamasaki T, Hasegawa S, Mori T, Horibe K. Prognostic value of minimal disseminated disease assessed using digital PCR for 3'ALK assays in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica. 2023 Sep 7. doi: 10.3324/haematol.2023.282812. (IF = 10.1)

  4. Ishiguro A, Nishioka M, Morishige A, Yoneshiro M, Shinkawa K, Fujinaga A, Kobayashi T, Suehiro Y, Yamasaki T. Determination of the Optimal Wavelength of the Hemolysis Index Measurement. J Clin Med. 2023 Sep 9;12(18):5864. (IF = 3.9/2022)

  5. Tanabe N, Saeki I, Aibe Y, Matsuda T, Hanazono T, Nishi M, Hidaka I, Kuwashiro S, Shiratsuki S, Matsuura K, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Sasaki R, Nishimura T, Oono T, Hisanaga T, Matsumoto T, Ishikawa T, Yamasaki T, Takami T. Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma. Cancers (Basel). 2023 May 26;15(11):2927. (IF = 5.2/2022)

  6. Saeki I, Suehiro Y, Yamauchi Y, Hoshida T, Tanabe N, Oono T, Kawamoto D, Nishimura T, Matsumoto T, Ishikawa T, Shimokawa M, Tamori A, Kawada N, Tamai Y, Iwasa M, Nakagawa H, Nagano H, Takami T, Yamasaki T. Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma. Hepatol Int. 2023 Oct;17(5):1289-1299. doi: 10.1007/s12072-023-10488-y. (IF = 6.6/2022)

  7. Saeki I, Yamasaki T, Yamauchi Y, Kawaoka T, Uchikawa S, Hiramatsu A, Aikata H, Kobayashi K, Kondo T, Ogasawara S, Chiba T, Kawano R, Chayama K, Kato N, Takami T. Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy. Cancer Med. 2023 May;12(9):10625-10635.  (IF = 4.0/2022)

  8. Yamauchi Y, Saeki I, Yamasaki T, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Nishimura T, Tanabe N, Oono T, Matsumoto T, Ishikawa T, Marumoto Y, Matsukuma S, Shindo Y, Tokumitsu Y, Yoshimine S, Murakami J, Tanaka T, Kimura S, Hoshii Y, Hamano K, Nagano H, Takami T. Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Hepatol Res. 2023 Jul;53(7):681-686.  (IF = 4.2/2022)

 

【2022】(IF = 49.7)

  1. Suehiro Y, Suenaga S, Kunimune Y, Yada S, Hamamoto K, Tsuyama T, Amano S, Matsui H, Higaki S, Fujii I, Suzuki C, Hoshida T, Matsumoto T, Fujimoto Y, Kaino S, Shinjo K, Kondo Y, Sakaida I, Takami T, Nagano H, Yamasaki T. CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer. 2022;100(12):674-684. (IF = 3.5/2022)

  2. Fujii T, Nishikawa J, Fukuda S, Kubota N, Nojima J, Fujisawa K, Ogawa R, Goto A, Hamabe K, Hashimoto S, Wai AP, Iizasa H, Yoshiyama H, Sakai K, Suehiro Y, Yamasaki T, Takami T. MC180295 Inhibited Epstein-Barr Virus-Associated Gastric Carcinoma Cell Growth by Suppressing DNA Repair and the Cell Cycle. Int J Mol Sci. 2022 Sep 13;23(18):10597. (IF = 5.6/2022)

  3. Yamaoka Y, Sasai M, Suehiro Y, Hashimoto S, Goto A, Yamamoto N, Suzuki N, Higaki S, Fujii I, Suzuki C, Matsumoto T, Hoshida T, Koga M, Tsutsumi T, Lim LA, Matsubara Y, Tomochika S, Yoshida S, Hazama S, Yotsuyanagi H, Nagano H, Sakaida I, Takami T, Yamasaki T. Comparison of two primer-probe sets of Fusobacterium nucleatum using droplet digital polymerase chain reaction for the detection of colorectal neoplasia from faecal samples. Ann Clin Biochem. 2022 Nov;59(6):396-403. (IF = 2.2/2022)

  4. Yamasaki T, Saeki I, Yamauchi Y, Matsumoto T, Suehiro Y, Kawaoka T, Uchikawa S, Hiramatsu A, Aikata H, Kobayashi K, Kondo T, Ogasawara S, Chiba T, Takami T, Chayama K, Kato N, Sakaida I. Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. Liver Cancer. 2022;11(4):329–40. (IF = 13.8/2022)

  5. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Ogasawara S, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y, on behalf of the TACTICS Study Group. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer. 2022;11(4):354–67. (IF = 13.8/2022)

  6. Fukuda S, Nishikawa J, Kobayashi Y, Okabe Y, Fujii T, Kubota N, Otsuyama KI, Tsuneoka H, Hashimoto S, Suehiro Y, Yamasaki T, Takami T. The bactericidal effect of far-UVC on ESBL-producing Escherichia coli. Am J Infect Control. 2022 May 13:S0196-6553(22)00409-6. (IF = 4.9/2022)

  7. Fujisawa K, Takami T, Matsumoto T, Yamamoto N, Yamasaki T, Sakaida I. An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells. Cancer Metab. 2022 May 12;10(1):8. (IF = 5.9/2022)

 

【2021】(IF = 32.4)

  1. Kobayashi T, Ichihara K, Goda S, Hidaka I, Yamasaki T, Ishida H. Exploration and time-serial validation of logistic regression models composed of multiple laboratory tests for early detection of HCV-associated hepatocellular carcinoma. Clin Chim Acta. 2021 Oct;521:137-143. (IF = 5.0/2021)

  2. Takahashi H, Okayama N, Natsu Yamaguchi N, Nomura M, Miyahara Y, Mahbub MH, Hase R, Morishima Y, Suehiro Y, Yamasaki T, Tamada K, Takahashi S, Tojo A, Tanabe T. Analysis of Relationships between Immune Checkpoint and Methylase Gene Polymorphisms and Outcomes after Unrelated Bone Marrow Transplantation. 2021 Jun 1; 13(11): 2752. (IF = 5.2/2022)

  3. Saeki I, Yamasaki T, Yamauchi Y, Takami T, Kawaoka T, Uchikawa S, Hiramatsu A, Aikata H, Kawano R, Kobayashi K, Kondo T, Ogasawara S, Chiba T, Chayama K, Kato N, Sakaida I. Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. 2021 May 7;13(9):2247. (IF = 5.2/2022)

  4. Kotoh Y, Saeki I, Yamasaki T, Sasaki R, Tanabe N, Oono T, Maeda M, Hidaka I, Ishikawa T, Takami T, Sakaida I. Albumin-bilirubin score as a useful predictor of energy malnutrition in patients with hepatocellular carcinoma. Clin Nutr. 2021 May;40(5):3585-3591. (IF = 6.3/2022)

  5. Yamasaki T, Saeki I, Kotoh-Yamauchi Y, Sasaki R, Tanabe N, OonoT, Matsuda T, Takuro Hisanaga T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Suehiro Y, Sakaida I. Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma. Appl Sci(Basel). 2021 Feb 20; 11(4): 1882. (IF = 2.7/2022)

  6. Fukuda S, Ito S, Nishikawa J, Takagi T, Kubota N, Otsuyama K, Tsuneoka H, Nojima J, Harada K, Mishima K, Suehiro Y, Yamasaki T, Sakaida I. Deep Ultraviolet Light-emitting Diode Light Therapy for Fusobacterium Nucleatum. Microorganisms. 2021 Feb 19;9(2):430. (IF = 4.5/2022)

  7. Fujimoto Y, Suehiro Y, Kaino S, Suenaga S, Tsuyama T, Matsui H, Higaki S, Fujii I, Suzuki C, Hoshida T, Matsumoto T, Takami T, Nagano H, Sakaida I, Yamasaki T. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer. 2021 Jan 13:1-6. (IF = 3.5/2022)

 

【2020】(IF = 72.4)

  1. Nishi M, Matsumoto T, Fujisawa K, Suehiro Y, Takami T, Yamamoto N, Yamasaki T, Sakaida I. Mesenchymal stem cells induce a fibrolytic phenotype by regulating mmu-miR-6769b-5p expression in macrophages. Stem Cells Dev. 2020 Nov 15;29(22):1457-1466. (IF = 4.0/2022)

  2. Takagi T, Nishikawa J, Yanagihara M, Fukuda S, Kubota N, Kobayashi Y, Otsuyama KI, Nojima J, Tsuneoka H, Sakai K, Suehiro Y, Yamasaki T, Sakurai K, Itatani K, Sakaida I. Microbicidal effect of deep ultraviolet light-emitting diode irradiation. Lasers Med Sci. 2020 Sep 9. doi: 10.1007/s10103-020-03143-7. (IF = 2.1/2022)

  3. Kotoh Y, Saeki I, Yamasaki T, Sasaki R, Tanabe N, Oono T, Matsuda T, Hisanaga T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib. Appl Sci(Basel). 2020 Aug 5;10(16):5403. (IF = 2.7/2022)

  4. Ishiguro A, Nishioka M, Morishige A, Kawano R, Kobayashi T, Fujinaga A, Takagi F, Kogo T, Morikawa Y, Okayama N, Mizuno H, Aihara M, Suehiro Y, Yamasaki T. What is the best wavelength for the measurement of hemolysis index? Clin Chim Acta. 2020 Nov;510:15-20. (IF = 5.0/2022)

  5. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020 Aug;69(8):1492-1501. (IF =24.5/2022)

  6. Suehiro Y, Hashimoto S, Goto A, Yamaoka Y, Yamamoto N, Suzuki N, Higaki S, Fujii I, Suzuki C, Matsumoto T, Hoshida T, Koga M, Tsutsumi T, Lim LA, Matsubara Y, Takami T, Yoshida S, Hazama S, Yotsuyanagi H, Nagano H, Sakaida I, Yamasaki T. Fecal DNA Testing of TWIST1 Methylation Identifies Patients With Advanced Colorectal Adenoma Missed by Fecal Immunochemical Test for Hemoglobin. Clin Transl Gastroenterol. 2020 Jun;11(6):e00176. (IF = 3.6/2022)

  7. Hideura E, Suehiro Y, Nishikawa J, Shuto T, Fujimura H, Ito S, Goto A, Hamabe K, Saeki I, Okamoto T, Higaki S, Fujii I, Suzuki C, Hoshida T, Matsumoto T, Takami T, Sakaida I, Yamasaki T. Blood Free-Circulating DNA Testing of Methylated RUNX3 Is Useful for Diagnosing Early Gastric Cancer. (Basel). 2020 Mar 26;12(4):E789. (IF = 5.2/2022)

  8. Saeki I, Yamasaki T, Yamashita S, Hanazono T, Urata Y, Furutani T, Yokoyama Y, Oishi T, Maeda M, Kimura T, Kotoh Y, Sasaki R, Miyaji T, Oono T, Aibe Y, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment. (Basel). 2020 Mar 25;12(4). pii: E779. (IF = 5.2/2022)

  9. Kotoh Y, Suehiro Y, Saeki I, Hoshida T, Maeda M, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Higaki S, Fujii I, Suzuki C, Shindo Y, Tokumitsu Y, Nagano H, Sakaida I, Yamasaki T. Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma. Hepatol Commun. 2020 Jan 2;4(3):461-470. (IF = 5.1/2021)

  10. Maeda M, Saeki I, Sakaida I, Aikata H, Araki Y, Ogawa C, Kariyama K, Nouso K, Kitamoto M, Kobashi H, Sato S, Shibata H, Joko K, Takaki S, Takabatake H, Tsutsui A, Takaguchi K, Tomonari T, Nakamura S, Nagahara T, Hiraoka A, Matono T, Koda M, Mandai M, Mannami T, Mitsuda A, Moriya T, Yabushita K, Tani J, Yagi T, Yamasaki T. Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients. Liver Cancer. 2020 Jan;9(1):50-62. (IF = 13.8/2022)

  11. Ishikawa T, Sasaki R, Nishimura T, Iwamoto T, Takami T, Yamasaki T, Sakaida I. Improved Hepatic Reserve and Fibrosis in a Case of "Portal-Systemic Liver Failure" by Portosystemic Shunt Occlusion. Am J Case Rep. 2020 Feb 17;21:e921236. (IF = 1.2/2022)

 

【2019】(IF = 31.8)

  1. Shuto T, Nishikawa J, Shimokuri K, Yanagi A, Takagi T, Takagi F, Miura O, Iida M, Nagano H, Takemoto Y, Harada E, Suehiro Y, Yamasaki T, Okamoto T, Sakaida I. Establishment of a Screening Method for Epstein-Barr Virus-Associated Gastric Carcinoma by Droplet Digital PCR. Microorganisms. 2019 Nov 29;7(12). pii: E628. (IF = 4.5/2022)

  2. Yanagi A, Nishikawa J, Shimokuri K, Shuto T, Takagi T, Takagi F, Kobayashi Y, Yamamoto M, Miura O, Yanai H, Suehiro Y, Yamasaki T, Yoshiyama H, Sakaida I. Clinicopathologic Characteristics of Epstein-Barr Virus-Associated Gastric Cancer Over the Past Decade in Japan. Microorganisms. 2019 Sep 1;7(9). pii: E305. (IF = 4.5/2022)

  3. Maeda H, Hazama S, Iwamoto S, Oba K, Tsunedomi R, Okayama N, Suehiro Y, Yamasaki T, Nakagami Y, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials. Oncol Lett. 2019 Nov;18(5):4555-4562. (IF = 2.9/2022)

  4. Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu Y, Iida M, Tsunedomi R, Takeda S, Yoshino S, Okayama N, Suehiro Y, Yamasaki T, Fujita T, Kawakami Y, Ueno T, Nagano H. Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. Br J Cancer. 2019 Oct;121(8):659-665. (IF = 8.8/2022)

  5. Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy. PLoS One. 2019 Jun 13;14(6):e0218136. (IF = 3.7/2022)

  6. Hanazono T, Hidaka I, Maeda M, Saeki I, Iwamoto T, Ishikawa T, Takami T, Yamasaki T, Sakaida I. Utility of Real-time Tissue Elastography in the Sequential Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis C. The bulletin of the Yamaguchi Medical School. 2019 Jun;66(1-2):29-35. (IF =NA/2022)

  7. Fukui Y, Saeki I, Matsuda T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Yamasaki T, Sakaida I. Utility of Contrast-Enhanced Ultrasonography for the Evaluation of Partial Splenic Embolization. The bulletin of the Yamaguchi Medical School. 2019 Jun;66(1-2):7-13. (IF =NA/2022)

  8. Sasaki S, Nishikawa J, Sakai K, Iizasa H, Yoshiyama H, Yanagihara M, Shuto T, Shimokuri K, Kanda T, Suehiro Y, Yamasaki T, Sakaida I. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. Gastric Cancer. 2019 May;22(3):486-496. (IF = 7.4/2022)

 

【2018】(IF = 50.3)

  1. Saeki I, Yamasaki T, Maeda M, Kawano R, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma. Liver Cancer. 2018 Oct;7(4):359-371. (IF = 13.8/2022)

  2. Iwamoto S, Maeda H, Hazama S, Oba K, Okayama N, Suehiro Y, Yamasaki T, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer. J Cancer. 2018 Oct 18;9(22):4092-4098. (IF = 3.9/2022)

  3. Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol. 2018 Sep 27;10(9):571-584. (IF = 2.4/2022)

  4. Shinoda S, Kaino S, Amano S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto N, Yamasaki T, Sakaida I. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. Oncotarget. 2018 Jun 19;9(47):28434-28444. (IF = NA/2022)

  5. Nishikawa J, Iizasa H, Yoshiyama H, Shimokuri K, Kobayashi Y, Sasaki S, Nakamura M, Yanai H, Sakai K, Suehiro Y, Yamasaki T, Sakaida I. Clinical Importance of Epstein⁻Barr Virus-Associated Gastric Cancer. Cancers (Basel). 2018 May 29;10(6). pii: E167. (IF = 5.2/2022)

  6. Suehiro Y, Hashimoto S, Higaki S, Fujii I, Suzuki C, Hoshida T, Matsumoto T, Yamaoka Y, Takami T, Sakaida I, Yamasaki T. Blood free-circulating DNA testing by highly sensitive methylation assay to diagnose colorectal neoplasias. Oncotarget. 2018 Mar 30;9(24):16974-16987. (IF = NA/2022)

  7. Fujisawa K, Takami T, Okada S, Hara K, Matsumoto T, Yamamoto N, Yamasaki T, Sakaida I. Analysis of Metabolomic Changes in Mesenchymal Stem Cells on Treatment with Desferrioxamine as a Hypoxia Mimetic Compared with Hypoxic Conditions. Stem Cells. 2018 Aug;36(8):1226-1236. (IF = 5.2/2022)

  8. Nishioka M, Suehiro Y, Sakai K, Matsumoto T, Okayama N, Mizuno H, Ueno K, Suzuki N, Hashimoto S, Takami T, Hazama S, Nagano H, Sakaida I, Yamasaki T. TROY is a promising prognostic biomarker in patients with colorectal cancer. Oncol Lett. 2018 Apr;15(4):5989-5994. (IF = 2.9/2022)

  9. Nishi M, Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Hemobilia immediately after transcatheter arterial chemoembolization using drug-eluting beads for hepatocellular carcinoma with intrahepatic bile duct invasion. Hepatol Res. 2018 Mar;48(4):329-332. (IF = 4.2/2022)

  10. Yamaoka Y, Suehiro Y, Hashimoto S, Hoshida T, Fujimoto M, Watanabe M, Imanaga D, Sakai K, Matsumoto T, Nishioka M, Takami T, Suzuki N, Hazama S, Nagano H, Sakaida I, Yamasaki T. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol. 2018 Apr;53(4):517-524. (IF = 6.3/2022)

  11. Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Evaluation of the "assessment for continuous treatment with hepatic arterial infusion chemotherapy" scoring system in patients with advanced hepatocellular carcinoma. Hepatol Res. 2018 Feb;48(3):E87-E97. (IF = 4.2/2022)

  12. Suehiro Y, Zhang Y, Hashimoto S, Takami T, Higaki S, Shindo Y, Suzuki N, Hazama S, Oka M, Nagano H, Sakaida I, Yamasaki T. Highly sensitive faecal DNA testing of TWIST1 methylation in combination with faecal immunochemical test for haemoglobin is a promising marker for detection of colorectal neoplasia. Ann Clin Biochem. 2018 Jan;55(1):59-68. (IF = 2.2/2022)

 

【2017】(IF = 31.4)

  1. Takahashi H, Okayama N, Yamaguchi N, Miyahara Y, Morishima Y, Suehiro Y, Yamasaki T, Tamada K, Takahashi S, Tojo A, Asano S, Tanabe T. Associations of interactions between NLRP3 SNPs and HLA mismatch with acute and extensive chronic graft-versus-host diseases. Sci Rep. 2017 Oct 12;7(1):13097. (IF = 4.6/2022)

  2. Asada Y, Morimoto Y, Nakaoka Y, Yamasaki T, Suehiro Y, Sugimoto H, Yoshida M, Irahara M. Age-specific serum anti-Müllerian hormone concentration in Japanese women and its usefulness as a predictor of the ovarian response. Reprod Med Biol. 2017 Sep 18;16(4):364-373. (IF = 3.4/2022)

  3. Nishikawa J, Iizasa H, Yoshiyama H, Nakamura M, Saito M, Sasaki S, Shimokuri K, Yanagihara M, Sakai K, Suehiro Y, Yamasaki T, Sakaida I. The Role of Epigenetic Regulation in Epstein-Barr Virus-Associated Gastric Cancer. Int J Mol Sci. 2017 Jul 25;18(8). pii: E1606. (IF = 5.6/2022)

  4. Yamamoto Y, Suehiro Y, Suzuki A, Nawata R, Kawai Y, Inoue R, Hirata H, Matsumoto H, Yamasaki T, Sasaki K, Matsuyama H. Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression. Oncol Lett. 2017 Jul;14(1):1193-1199. (IF = 2.9/2022)

  5. Nakamura M, Nishikawa J, Saito M, Sakai K, Sasaki S, Hashimoto S, Okamoto T, Suehiro Y, Yamasaki T, Sakaida I. Decitabine inhibits tumor cell proliferation and up-regulates e-cadherin expression in Epstein-Barr virus-associated gastric cancer. J Med Virol. 2017 Mar;89(3):508-517. (IF = 12.7/2022)

  6. Suehiro Y, Sakai K, Nishioka M, Hashimoto S, Takami T, Higaki S, Shindo Y, Hazama S, Oka M, Nagano H, Sakaida I, Yamasaki T. Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population. Ann Clin Biochem. 2017 Jan;54(1):86-91. (IF = 2.2/2022)

 

【2016】(IF = 30.3)

  1. Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol. 2016 Oct 28;22(40):8967-8977. (IF = 4.3/2022)

  2. Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol. 2016 Aug 28;22(32):7252-63. (IF = 4.3/2022)

  3. Harima H, Kaino S, Takami T, Shinoda S, Matsumoto T, Fujisawa K, Yamamoto N, Yamasaki T, Sakaida I. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. BMC Cancer. 2016 Aug 31;16:702. (IF = 3.8/2022)

  4. Yamamoto N, Yamasaki T, Takami T, Uchida K, Fujisawa K, Matsumoto T, Saeki I, Terai S, Sakaida I. Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib. J Clin Biochem Nutr. 2016 May;58(3):202-9. (IF = 2.4/2022)

  5. Fujisawa K, Terai S, Takami T, Yamamoto N, Yamasaki T, Matsumoto T, Yamaguchi K, Owada Y, Nishina H, Noma T, Sakaida I. Modulation of anti-cancer drug sensitivity through the regulation of mitochondrial activity by adenylate kinase 4. J Exp Clin Cancer Res. 2016 Mar 16;35:48. (IF = 11.3/2022)

  6. Urata Y, Yamasaki T, Saeki I, Iwai S, Kitahara M, Sawai Y, Tanaka K, Aoki T, Iwadou S, Fujita N, Nakayama Y, Maeshiro T, Takami T, Sakaida I. Clinical characteristics and prognosis of non-B non-C hepatocellular carcinoma patients with modest alcohol consumption. Hepatol Res. 2016 Mar;46(5):434-42. (IF = 4.2/2022)

 

【2015】(IF = 6.6)

  1. Saeki I, Yamasaki T, Tanabe N, Iwamoto T, Matsumoto T, Urata Y, Hidaka I, Ishikawa T, Takami T, Yamamoto N, Uchida K, Terai S, Sakaida I. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS One. 2015 May 20;10(5):e0126649. (IF = 3.7/2022)

  2. Zhang Y, Suehiro Y, Shindo Y, Sakai K, Hazama S, Higaki S, Sakaida I, Oka M, Yamasaki T. Long-fragment DNA as a potential marker for stool-based detection of colorectal cancer. Oncol Lett. 2015 Jan;9(1):454-458. (IF = 2.9/2022)

 

【2014】(IF = 58.7)

  1. Nishikawa J, Yoshiyama H, Iizasa H, Kanehiro Y, Nakamura M, Nishimura J, Saito M, Okamoto T, Sakai K, Suehiro Y, Yamasaki T, Oga A, Yanai H, Sakaida I. Epstein-barr virus in gastric carcinoma. Cancers (Basel). 2014 Nov 7;6(4):2259-74. (IF = 5.2/2022)

  2. Ooishi T, Saeki I, Yamasaki T, Sakaida I. Hepatocellular carcinoma-induced hemobilia. Intern Med. 2014;53(14):1579. (IF= 1.2/2022)

  3. Tsunedomi R, Hazama S, Fujita Y, Okayama N, Kanekiyo S, Inoue Y, Yoshino S, Yamasaki T, Suehiro Y, Oba K, Mishima H, Sakamoto J, Hamamoto Y, Oka M. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. Int J Oncol. 2014 Oct;45(4):1381-90. (IF = 5.2/2022)

  4. Marumoto M, Yamasaki T, Marumoto Y, Saeki I, Harima Y, Urata Y, Hidaka I, Ishikawa T, Takami T, Segawa M, Yamaguchi Y, Uchida K, Terai S, Sakaida I. Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study. Hepatogastroenterology. 2014 Jan-Feb;61(129):162-7. (IF = NA/2022)

  5. Ishikawa T, Shiratsuki S, Matsuda T, Iwamoto T, Takami T, Uchida K, Terai S, Yamasaki T, Sakaida I. Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension. J Gastroenterol. 2014 Sep;49(9):1333-41. (IF = 6.3/2022)

  6. Oono T, Yamasaki T, Zaitsu J, Saeki I, Iwamoto T, Harima Y, Marumoto Y, Hidaka I, Urata Y, Ishikawa T, Takami T, Segawa M, Uchida K, Terai S, Kunitugu I, Tanabe T, Sakaida I. Association of tyrosine with insulin resistance in hepatitis C virus-related chronic liver disease. Hepatol Res. 2014 Oct;44(10):E54-62. (IF = 4.2/2022)

  7. Inoue Y, Hazama S, Iwamoto S, Miyake Y, Matsuda C, Tsunedomi R, Okayama N, Hinoda Y, Yamasaki T, Suehiro Y, Yoshino S, Sakamoto J, Mishima H, Oka M. FcγR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer. Mol Diagn Ther. 2014 Oct;18(5):541-8. (IF = 4.0/2022)

  8. Terai S, Takami T, Yamamoto N, Fujisawa K, Ishikawa T, Urata Y, Tanimoto H, Iwamoto T, Mizunaga Y, Matsuda T, Oono T, Marumoto M, Burganova G, Fernando Quintanilha L, Hidaka I, Marumoto Y, Saeki I, Uchida K, Yamasaki T, Tani K, Taura Y, Fujii Y, Nishina H, Okita K, Sakaida I. Status and prospects of liver cirrhosis treatment by using bone marrow-derived cells and mesenchymal cells. Tissue Eng Part B Rev. 2014 Jun;20(3):206-10. (IF = 6.4/2022)

  9. Zaitsu J, Yamasaki T, Saeki I, Harima Y, Iwamoto T, Harima Y, Matsumoto T, Urata Y, Hidaka I, Marumoto Y, Ishikawa T, Takami T, Yamamoto N, Kaino S, Uchida K, Terai S, Sakaida I. Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. Hepatol Res. 2014 May;44(5):481-90. (IF = 4.2/2022)

  10. Shindo Y, Hazama S, Maeda Y, Matsui H, Iida M, Suzuki N, Yoshimura K, Ueno T, Yoshino S, Sakai K, Suehiro Y, Yamasaki T, Hinoda Y, Oka M. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. J Transl Med. 2014 Jun 19;12:175. (IF = 7.4/2021)

  11. Yamasaki T, Saeki I, Sakaida I. Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments. Hepatol Int. 2014 Sep;8 Suppl 2:492-8. (IF = 6.6/2021)

bottom of page